A1 Refereed original research article in a scientific journal

Optimized detection of homologous recombination deficiency improves the prediction of clinical outcomes in cancer




AuthorsPerez-Villatoro Fernando, Oikkonen Jaana, Casado Julia, Chernenko Anastasiya, Gulhan Doga C., Tumiati Manuela, Li Yilin, Lavikka Kari, Hietanen Sakari, Hynninen Johanna, Haltia Ulla-Maija, Tyrmi Jaakko S., Laivuori Hannele, Konstantinopoulos Panagiotis A., Hautaniemi Sampsa, Kauppi Liisa, Färkkilä Anniina

PublisherNature Portfolio

Publication year2022

Journalnpj Precision Oncology

Journal name in sourceNPJ PRECISION ONCOLOGY

Journal acronymNPJ PRECIS ONCOL

Article number 96

Volume6

Number of pages13

eISSN2397-768X

DOIhttps://doi.org/10.1038/s41698-022-00339-8(external)

Web address https://doi.org/10.1038/s41698-022-00339-8(external)

Self-archived copy’s web addresshttps://research.utu.fi/converis/portal/detail/Publication/178371373(external)


Abstract
Homologous recombination DNA-repair deficiency (HRD) is a common driver of genomic instability and confers a therapeutic vulnerability in cancer. The accurate detection of somatic allelic imbalances (AIs) has been limited by methods focused on BRCA1/2 mutations and using mixtures of cancer types. Using pan-cancer data, we revealed distinct patterns of AIs in high-grade serous ovarian cancer (HGSC). We used machine learning and statistics to generate improved criteria to identify HRD in HGSC (ovaHRDscar). ovaHRDscar significantly predicted clinical outcomes in three independent patient cohorts with higher precision than previous methods. Characterization of 98 spatiotemporally distinct metastatic samples revealed low intra-patient variation and indicated the primary tumor as the preferred site for clinical sampling in HGSC. Further, our approach improved the prediction of clinical outcomes in triple-negative breast cancer (tnbcHRDscar), validated in two independent patient cohorts. In conclusion, our tumor-specific, systematic approach has the potential to improve patient selection for HR-targeted therapies.

Downloadable publication

This is an electronic reprint of the original article.
This reprint may differ from the original in pagination and typographic detail. Please cite the original version.





Last updated on 2024-26-11 at 11:13